NCT07462130

An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)

A Phase Ib/II, Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 74 (estimated)
• Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease

Conditions

• Thyroid Eye Disease

Interventions

Type	Name	Description
DRUG	NTB003	NTB003 dose 1 administered SC injection every 4 weeks.
DRUG	NTB003	NTB003 dose 2 administered SC injection every 4 weeks.
DRUG	NTB003	NTB003 dose 3 administered SC injection every 4 weeks.
DRUG	NTB003 and Placebo	Drug:NTB003 subcutaneous injection Drug: Placebo subcutaneous injection

Timeline

• Start date: 2026-03-01
• Primary completion: 2027-05-31
• Completion: 2028-03-30
• First posted: 2026-03-10
• Last updated: 2026-03-10